



9/30/04

1FW

PTO/SB/21 (04-04)

**TRANSMITTAL
FORM**

(to be used for all correspondence after initial filing)

Total Number of Pages in This Submission

5

Application Number	10/699,517
Filing Date	October 31, 2003
First Named Inventor	Schenk, Dale B.
Art Unit	1646
Examiner Name	Unassigned

Attorney Docket Number 015270-008920US

ENCLOSURES (Check all that apply)

<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> After Allowance Communication to Technology Center (TC) <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): <input type="checkbox"/> Return Postcard
<input type="checkbox"/> Amendment/Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s)	<input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation <input type="checkbox"/> Change of Correspondence Address	
<input type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Terminal Disclaimer	
<input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> Request for Refund	
<input checked="" type="checkbox"/> Supplemental Information Disclosure Statement (2 pp.) PTO/SB08A (1 pg.) PTO/SB08B (1 pg.) *references AA-AO	<input type="checkbox"/> CD, Number of CD(s) _____	
<input type="checkbox"/> Certified Copy of Priority Document(s)	Remarks The Commissioner is authorized to charge any additional fees to Deposit Account 20-1430.	
<input type="checkbox"/> Response to Missing Parts/ Incomplete Application	*Not included in the "Total Number of Pages In This Submission"	
<input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm or Individual name	Townsend and Townsend and Crew LLP Rosemarie L. Celli	Reg. No. 42,397
Signature		
Date	September 28, 2004	

CERTIFICATE OF TRANSMISSION/MAILING

Express Mail Label: EV 337295142 US

I hereby certify that this correspondence is being deposited with the United States Postal Service with "Express Mail Post Office to Address" service under 37 CFR 1.10 on this date August 5, 2004 and is addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below.

Typed or printed name	Daniel Miranda		
Signature		Date	September 28, 2004



PATENT
Attorney Docket No.: 015270-008920US
Client Reference No.: 334-US-NEW2

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Dale B. Schenk et al.

Application No.: 10/699,517

Filed: October 31, 2003

For: PREVENTION AND TREATMENT
OF SYNUCLEINOPATHIC DISEASE

Examiner: Unassigned

Art Unit: 1646

**SUPPLEMENTAL INFORMATION
DISCLOSURE STATEMENT UNDER 37
CFR §1.97 and §1.98**

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450


Sir:

The references cited on the attached PTO/SB/08A and PTO/SB/08B forms are being called to the attention of the Examiner. Copies of the references are enclosed. It is respectfully requested that the cited references be expressly considered during the prosecution of this application, and the references be made of record therein and appear among the "references cited" on any patent to issue therefrom.

As provided for by 37 CFR 1.97(g) and (h), no representation is being made that a search has been conducted or that this statement encompasses all the possible relevant information, and no inference should be made that the information and references cited are, or are considered to be material to patentability because they are in this statement. No inference should be made that the information and references cited are prior art merely because they are in this statement.


Applicant believes that no fee is required for submission of this statement. However, if a fee is required, the Commissioner is authorized to deduct such fee from the undersigned's Deposit Account No. 20-1430. Please deduct any additional fees from, or credit any overpayment to, the above-noted Deposit Account.

Respectfully submitted,



Rosemarie L. Celli
Reg. No. 42,397

TOWNSEND and TOWNSEND and CREW LLP
Two Embarcadero Center, Eighth Floor
San Francisco, California 94111-3834
Tel: 650-326-2400
Fax: 650-326-2422
RLC:crf
60307804 v1

Substitute for form 1449A/PTO		SEP 28 2004		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Application Number	10/699,517
		Filing Date	October 31, 2003		
		First Named Inventor	Schenk, Dale B.		
		Art Unit	1646		
		Examiner Name	Unassigned		
		Attorney Docket Number	015270-008920US		
Sheet	1	of	2		

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

¹EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ² Applicant's unique citation designation number (optional). ³ Kind Codes of U.S. Patent Documents at www.uspto.gov or MPEP 901.04. ⁴ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁵ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁶ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁷ Applicant is to place a check mark here if English language Translation is attached.



Institute for form 1449B/PTO				Complete if Known	
				Application Number	10/699,517
				Filing Date	October 31, 2003
				First Named Inventor	Schenk, Dale B.
				Art Unit	1646
				Examiner Name	Unassigned
Sheet	2	of	2	Attorney Docket Number	015270-008920US

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		T ²
	AF	BODLES et al., "Toxicity of non- $\text{A}\beta$ ' component of Alzheimer's disease amyloid, and N-terminal fragments thereof, correlates to formation of β -sheet structure and fibrils," <i>Eur J. Biochem.</i> , 267:2186-2194 (2000).		
	AG	CAO et al., "Development of an Alpha Synuclein Recombinant Protein as a Potential Candidate Against Parkinson's Disease," Program No. 594.13, Abstract Viewer/Itinerary Planner, Washington D.C.: Society for Neuroscience, 2002.		
	AH	CULVENOR et al., "Non- $\text{A}\beta$ Component of Alzheimer's Disease Amyloid (NAC) Revisited, NAC and α -Synuclein Are Not Associated with $\text{A}\beta$ Amyloid," <i>Am. J. Pathology</i> , 155(4):1173-1181 (1999).		
	AI	HASHIMOTO et al., "Alpha-synuclein in Lewy Body Disease and Alzheimer's Disease," <i>Brain Pathology</i> , 9:707-720 (1999).		
	AJ	HSU et al., " α -Synuclein Promotes Mitochondrial Deficit and Oxidative Stress," <i>Am. J. Pathology</i> , 157(2):401-410 (2000).		
	AK	JENSEN et al., "Residues in the synuclein consensus motif of the alpha-synuclein fragment, NAC, participate in transglutaminase-catalysed cross-linking to Alzheimer-disease amyloid beta A4 peptide," <i>Biochem. J.</i> , 310(Pt 1):91-94 (1995).		
	AL	MASLIAH et al., "Dopaminergic Loss and Inclusion Body Formation in α -Synuclein Mice: Implications for Neurodegenerative Disorders," <i>Science</i> , 287:1265-1268 (2000).		
	AM	NCBI database search result for P37840 Alpha-synuclein conducted 10/21/02 at http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&DB=protein&list_uids=58		
	AN	NCBI database search result for NP_009292 synuclein, alpha conducted 10/21/02 at http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=protein&list_uids=68		
	AO	UEDA et al., "Molecular cloning of cDNA encoding an unrecognized component of amyloid in Alzheimer disease," <i>PNAS</i> , 90:11282-11286 (1993).		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.